Colorado Capital Management Inc. Boosts Position in Novo Nordisk A/S (NYSE:NVO)

Colorado Capital Management Inc. lifted its position in Novo Nordisk A/S (NYSE:NVO) by 16.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,229 shares of the company’s stock after purchasing an additional 589 shares during the period. Colorado Capital Management Inc.’s holdings in Novo Nordisk A/S were worth $364,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Hsbc Holdings PLC raised its holdings in shares of Novo Nordisk A/S by 19.4% in the 2nd quarter. Hsbc Holdings PLC now owns 54,804 shares of the company’s stock valued at $7,852,000 after acquiring an additional 8,922 shares in the last quarter. AE Wealth Management LLC raised its stake in Novo Nordisk A/S by 161.5% in the second quarter. AE Wealth Management LLC now owns 19,319 shares of the company’s stock valued at $2,758,000 after purchasing an additional 11,930 shares in the last quarter. Epoch Investment Partners Inc. lifted its position in Novo Nordisk A/S by 4.5% during the second quarter. Epoch Investment Partners Inc. now owns 14,132 shares of the company’s stock valued at $2,017,000 after purchasing an additional 614 shares during the last quarter. Gabelli Funds LLC grew its stake in Novo Nordisk A/S by 35.7% in the 2nd quarter. Gabelli Funds LLC now owns 46,963 shares of the company’s stock worth $6,703,000 after buying an additional 12,363 shares in the last quarter. Finally, DRW Securities LLC bought a new position in shares of Novo Nordisk A/S in the 2nd quarter worth $1,298,000. 11.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NVO has been the subject of several research reports. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Down 5.2 %

Shares of NYSE NVO opened at $78.74 on Tuesday. The firm’s fifty day moving average is $97.76 and its 200 day moving average is $116.89. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company has a market cap of $353.33 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.